Mutations Defining Patient Cohorts With Elevated PD-L1 Expression in Gastric Cancer

Otilia Menyhárt1,2, Lőrinc Sándor Pongor1,2 and Balázs Györfy1,2*

1 2nd Department of Pediatrics, Semmelweis University, Budapest, Hungary, 2 MTA TTK Lendület Cancer Biomarker Research Group, Institute of Enzymology, Hungarian Academy of Sciences, Budapest, Hungary

The immunotherapy agent pembrolizumab has been approved for gastric cancer (GC) patients with recurrent or advanced disease who are PD-L1 positive. Mutations in the primary lesion may drive the expression of immune targets thereby priming the tumor to therapeutic sensitivity. In this study, we aimed to uncover mutations associated with elevated PD-L1 expression in GC patients. Data from 410 GC patients were available, including the mutational spectrum of 39,916 genes and expression values of 20,500 genes. PD-L1 gene expression was compared to the mutational status of each gene separately by using a Mann-Whitney U-test and a Receiver Operating Characteristic test. Only mutations with a prevalence over 5% were considered. Significance was accepted in cases of $p < 1E-05$ and a fold change over 1.44. Mutations in 209 genes were associated with increased PD-L1 expression. These mutations were enriched in genes related to microtubule-based movement ($p = 3.4E-4$), cell adhesion ($p = 4.9E-4$), response to DNA-damage ($p = 6.9E-4$), and double-strand break-repair ($p = 1.6E-3$). Mutations in TTK ($p = 8.8E-10$, AUC = 0.77), COL7A1 ($p = 2.0E-9$, AUC = 0.74), KIF15 ($p = 2.5E-9$, AUC = 0.75), and BDP1 ($p = 3.3E-9$, AUC = 0.74) had the strongest link to elevated PD-L1 expression. Finally, we established a decision tree based on mutations in PIK3CA, MEF2C, SLC11A1, and KIF15 capable to separate patient sub-cohorts with elevated PD-L1 expression. In summary, we identified mutations associated with elevated PD-L1 expression that facilitate the development of better prognostic biomarkers for GC, and might offer insight into the underlying tumor biology.

Keywords: immunotherapy, stomach cancer, immune checkpoint inhibitors, CD274, PIK3CA, TTK, KIF15

INTRODUCTION

Gastric cancer (GC) is the fifth most common cancer and the third leading cause of cancer-related mortality in both sexes worldwide with the highest mortality being observed in Eastern Asia, Central and Eastern Europe (Ferlay et al., 2015). Moreover, despite a steady decline in gastric cancer related mortality in the Western hemisphere (Malvezzi et al., 2010), population aging, a distinctive feature of developed countries, contributes once again to increasing trends (Menyhárt et al., 2018). Early diagnosis is difficult due to lack of symptoms, particularly in countries without active screening programs, while detection in an advanced stage limits survival prospects (Seeruttun et al., 2017). For advanced patients, standard treatment options based on combined chemotherapy regimens provide limited benefits, and the median overall survival is <12 months (Cunningham et al., 2010). In recent years, immune checkpoint inhibitors (ICI) have rapidly gained momentum in the treatment of advanced GCs and gastroesophageal junction cancers (GEJC) (Taieb et al., 2018).
The immune checkpoint receptor programmed cell death-1 (PD-1) is expressed on activated T cells and prevents overstimulation of immune responses (Francisco et al., 2010), while its ligand, PD-L1, is expressed on tumor infiltrating immune cells and tumor cells. The PD-1/PD-L1 pathway plays an active role in tumor immune evasion (Henick et al., 2014). Blocking their interaction rescues T-cell-mediated anti-tumor immunity, providing a survival benefit in various advanced, refractory malignancies (Alsaab et al., 2017). The FDA granted accelerated approval to the anti-PD-1 monoclonal antibody pembrolizumab in 2017 as third line treatment for patients with recurrent, locally advanced or metastatic PD-L1-positive GC/GEJC (Fuchs et al., 2018). The anti-PD-1 agent nivolumab demonstrated survival benefits in refractory unresectable advanced or recurrent GC/GEJC, irrespective of PD-L1 expression status, leading to regulatory approval in Japan (Kang et al., 2017).

PD-1 and PD-L1 are expressed in up to 50% of GC/GEJC tumors and are usually associated with the poorest prognosis (Wu et al., 2015). PD-L1 expression is a potential predictive biomarker for the effectiveness of anti-PD-1 therapy: the objective response rate (ORR) to pembrolizumab monotherapy was 16% in PD-L1-positive vs. 6% in PD-L1-negative GC/GEJC patients. Responses were remarkably better when ICIs were administered as a first-line treatment: the ORR reached 36% in PD-L1-positive patients treated with pembrolizumab monotherapy (Fuchs et al., 2018).

PD-L1 status is typically detected by immunohistochemistry. Scoring methods, antibodies and cut-off values are different across clinical studies, making comparison difficult (Teng et al., 2018). Thus, additional biomarkers capable of identifying a subset of patients with elevated PD-L1 (CD274) expression as potential candidates for anti-PD-1 therapy are highly in demand.

Genetic alterations within tumors may influence immune system engagement eventually also impacting therapy response; in non-small cell lung cancer (NSCLC) cell lines EGFR mutations or EML4–ALK fusions activate the PD-1/PD-L1 pathway via PD-L1 upregulation, inducing immune escape (Akbay et al., 2013; Ota et al., 2015). Accordingly, anti-PD-1 therapy induced higher ORRs in PD-L1-positive EGFR mutant patients (31%) compared to EGFR wild-type (22%) NSCLC patients (Peters et al., 2017). KRAS mutant advanced NSCLC patients with simultaneous KEAP1/NFE2L2 mutations have reduced PD-L1 expression levels (Skoulidis et al., 2015), which eventually lead to decreased overall survival after the initiation of immune therapy (Arbour et al., 2018). In this study, our aim was to identify genetic alterations in GC that are associated with PD-L1 upregulation. These genes might serve as positive biomarkers capable of identifying responsive tumors. We also combined multiple genes with the goal of creating a decision tree to assist the selection of potentially eligible candidates for early anti-PD-1 therapy.

**METHODS**

**Sequencing and Expression Database**

Mutation and expression data were obtained from the TCGA repository (https://portal.gdc.cancer.gov/). Mutations identified with the mutect2 algorithm were downloaded in VCF format. Variants were selected based on the mutect2 “PASS” status and filtered for mutations with at least 50X overall coverage and a minimum of 5 reads supporting the alteration. The remaining mutations were annotated using the snpeff (Cingolani et al., 2012) program using the GRCh38 human genome version. Only the canonical isoforms were selected in the database construction. The expression database was normalized using the DESeq2 (Varet et al., 2016) algorithm.

**Classification Algorithm**

Gene expression for PD-L1 was compared to the mutational status of each gene separately using a non-parametric Mann-Whitney U-test and a Receiver Operating Characteristic analysis. Only mutations with a prevalence over 5% were considered. Because of the high number of genes evaluated, statistical significance was only accepted in case of $p < 1e-05$ and a fold change (FC) difference over 1.44. In addition, sensitivity, specificity, and area under the curve (AUC) values were computed for each gene.

Gene ontology analysis for the frequently mutated genes was performed using the Database for Annotation, Visualization and Integrated Discovery (DAVID) Bioinformatics Resource 6.8 to determine the biological meanings of functionally related gene groups (Huang Da et al., 2009). Step-up multiple testing correction was executed for multiple hypothesis testing (Györffy et al., 2005).

**Decision Tree**

A decision tree was calculated using the conditional inference tree method (Hothorn et al., 2006; Hothorn and Zeileis, 2015). The algorithm uses statistics measuring the association between responses and covariates. In the analysis, we used the univariate distribution to determine the significance. We set the maximum depth to 3 for the tree, and at least 5% of the samples were needed to establish a terminal node during the tree generation. The displayed tree includes the branched decision pipeline and the expression range of PD-L1 in the designated patient cohorts.

**RESULTS**

**Database Setup**

Data from 438 patients diagnosed with gastric cancer were available from the TCGA repository (https://cancergenome.nih.gov/). Most patients were diagnosed in clinical stage III and with grade 3 disease. 64% of the patients were male and 69% of patients were 60 years of age or older, with a median age of 67 years. The average follow-up time was 9.86 months, and 20% of patients died during this period. Over 8% of the patients were identified with residual disease, while pathological complete response (pCR) following adjuvant therapy occurred in 32.4% of the patients (for details see Supplemental Table 1).

**Mutations Associated With PD-L1 Expression**

On average, 873 mutation events were identified per patient in our population based on the mutational profile of 39,916 genes.
The most frequently mutated genes, *PCDHA1-PCDHA4* and the tumor suppressor *TP53*, were mutated on average in every second patient.

The expression levels of 20,500 genes were investigated in our patient population. Data consisting of both the mutational spectrum and expression values for all genes were available for 410 GC patients. Mutations in 209 genes were associated with significantly increased PD-L1 expression ([Supplemental Table 2](#)). Mutations in *TTK* (*p* = 8.83E-10, AUC = 0.77), *COL7A1* (*p* = 2E-9, AUC = 0.74), *KIF15* (*p* = 2.49E-9, AUC = 0.75), and *BDP1* (*p* = 3.26E-9, AUC = 0.75) presented the strongest link to elevated PD-L1 expression ([Figure 1](#)).

We performed gene enrichment analysis to determine the biological functions of the most frequent mutations. According to the GO analysis, the significantly mutated genes were involved in microtubule-based movement (*p* = 3.4E-4), cell adhesion (*p* = 4.9E-4), response to DNA-damage (*p* = 6.9E-4), regulation of gene expression (*p* = 1.5E-4), and homologous recombination-dependent double-strand break repair (*p* = 1.6E-3) ([Supplemental Table 3](#)).

**Mutation-Based Hierarchical Clustering**

The mutational status of multiple critical genes may assist in the selection of even stronger candidates for ICI therapy. Based on hierarchical clustering of all significant genes with mutational prevalence >5% (when considering the mutation as a terminal node) and FC of at least 1.44, we constructed a decision tree to stratify patients with differential PD-L1 expression ([Figure 2](#)). The mutational status of *PIK3CA* was the best performing root node dividing patients into major subclasses. Both *PIK3CA* wild-type and mutant populations could be subdivided using additional mutations. Approximately 73% of all patients harbored wild-type alleles of both *PIK3CA* and *KIF15* that are associated with significantly lower overall PD-L1 expression, while *PIK3CA* wild-type patients with *KIF15* mutations (6%) showed significantly elevated PD-L1 expression (*p* < 1e-03). Patients with *PIK3CA* mutations (21%) could be stratified by two further genes. The presence of *MEF2C* (*p* = 0.002) or *SLC11A1* (*p* < 0.001) mutations (4%) was linked to PD-L1 upregulation, while PD-L1 expression was lower in subjects with the wild-type alleles of *SLC11A1* (17%). Altogether 10% of all patients harbored mutations associated with PD-L1 overexpression.

**DISCUSSION**

Genetic aberrations within tumors may alter PD-1/PD-L1 interactions by modulating the expression of immune markers ([Skoulidis et al., 2015](#)) potentially affecting therapy response ([Arbour et al., 2018](#)). We identified mutations of 209 genes associated with PD-L1 upregulation in GC that are involved in functions, such as microtubule-based movement, cell adhesion, gene expression regulation, response to DNA damage and double-strand break repair. Mutations in the *TTK*, *COL7A1*, *KIF15*, and *BDP1* genes present the strongest association with elevated PD-L1 expression. *TTK* frameshift mutations appear in microsatellite instability-high (MSI-H) subtypes of GC that may alter cell cycle regulation ([Ahn et al., 2009](#)). Nonetheless, understanding the exact role of these genes in PD-L1 regulation requires further investigations.

To promote patient stratification, we created a decision tree capable of hypothetically prioritizing candidates for ICI therapy. The root node is set up by *PIK3CA*, while mutations involving *MEF2C*, *SLC11A1*, and *KIF15* provide additional sorting, all known to modulate various aspects of the immune system. *MEF2C* plays a role in immunity and leukemia development ([Schuler et al., 2008](#)), and was implicated as an oncogene in various hematological and solid cancers ([Pon and Marra, 2016](#)). *SLC11A1* encodes a transmembrane proton/divalent cation symporter, and participates in innate defense against pathogens by influencing macrophage activation ([Archer et al., 2015](#)). *KIF15* is involved in the maintenance of the mitotic spindle, and is upregulated in multiple solid malignancies ([Scanlan et al., 2001](#)); ([Wang et al., 2017](#)). *KIF15* also inhibits the endocytic trafficking of α2 integrin, implicated in various immune diseases ([De Fougerolles et al., 2000](#)). Except for *PIK3CA*, the functional relationship between the described mutations, PD-L1 upregulation and GC outcome is yet unexplored.

Our findings are in keeping with previous reports showing that gastric tumors with high PD-L1 expression levels frequently harbor *PIK3CA* mutations ([Cancer Genome Atlas Research Network, 2014](#)). In fact, *PIK3CA* is among the most frequently mutated genes in GC, present in ~32% of hypermutated and 12% of non-hypermutated tumors ([Cancer Genome Atlas Research Network, 2014](#)); ([Cristescu et al., 2015](#)). *PIK3CA* mutations are associated with more aggressive features, such as advanced T stage, poor differentiation and vascular invasion, especially in locoregional disease ([Kim et al., 2017](#)), and higher CD8+ T cell infiltration ([Siemers et al., 2017](#)). At the same time, *PIK3CA* mutations have not been directly linked to patient prognosis ([Harada et al., 2016](#)); ([Kim et al., 2017](#)). In this study, we found diversity within the *PIK3CA* mutant population, as additional genes were required to stratify patients based on differential PD-L1 expression.

The PI3K/Akt-pathway is involved in the immune response against malignant cells ([Dituri et al., 2011](#)), and increases the expression of immune markers. Inhibiting PI3K in melanoma cells reduced ([Jiang et al., 2013](#)), and knockdown of PTEN in colorectal cancer cell lines increased the expression of PD-L1 ([Song et al., 2013](#)). The PI3K/Akt-pathway regulates PD-L1 expression on a cell- and tissue-dependent manner by either transcriptional or post-transcriptional mechanisms ([Song et al., 2013](#)).

**PIK3CA** mutations appear with high frequency in Epstein-Barr virus positive and MSI-high subtypes of GC ([Cancer Genome Atlas Research Network, 2014](#)); ([Cristescu et al., 2015](#)), and *TTK* frameshift mutations are also relatively frequent in the latter ([Ahn et al., 2009](#)). These particular GC subtypes have been suggested to be the most promising candidates for immunotherapy ([Cancer Genome Atlas Research Network, 2014](#)); ([Cristescu et al., 2015](#)). In a recent clinical trial, MSI-high patients treated with ICI reached higher ORRs compared to patients with non-MSI-high tumors. However, the prevalence of MSI-high cases reached only 4% in the study population ([Fuchs et al., 2018](#)).
FIGURE 1 | Gene mutations defining higher PD-L1 expression. mRNA levels of PD-L1 (CD274) are significantly higher in TTK ($p = 8.8E-10$) and PIK3CA ($p = 1.7E-08$) mutant patients. The plots show Q1/Q2/Q3 within min–max range.

FIGURE 2 | Mutations in the PIK3CA, MEF2C, SLC11A1, and KIF15 genes help to stratify patients into subcohorts with dissimilar PD-L1 (CD274) expression. The decision tree was generated by analyzing the mutational status of all genes simultaneously with a minimal threshold of having at least 5% of the patients in each node. The plots show Q1/Q2/Q3 within min–max range.

Future trials will be required to clarify the subgroup specific responses to anti-PD-1 therapy.

In summary, we present an approach to narrow the list of potentially eligible patients for early anti-PD-1 therapy, and provide a foundation for future studies to reveal functional implications of key mutations on PD-L1 regulation. Nevertheless, the observed associations do not infer functional relationships.

Our results facilitate the development of prognostic biomarkers for GC, and offer insight into the underlying tumor biology.

**AUTHOR CONTRIBUTIONS**

BG contributed to the conception and design of the study. LP organized the data acquisition and analysis. OM wrote the
first draft of the manuscript. LP and BG wrote sections of the manuscript. All authors contributed to manuscript revision, read and approved the submitted version.

**FUNDING**

The study was supported by the KH-129581 and the NVKP_16-1-2016-0037 grants of the National Research, Development and Innovation Office, Hungary. The use of the computational infrastructure of Pázmány Péter University, provided within the National Bionics Program, is gratefully acknowledged.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2018.01522/full#supplementary-material

**REFERENCES**

Ahn, C. H., Kim, Y. R., Kim, S. S., Yoo, N. J., and Lee, S. H. (2009). Mutational analysis of TTK gene in gastric and colorectal cancers with microsatellite instability. *Cancer Res. Treat.* 41, 224–228. doi: 10.4143/crt.2009.41.4.224

Akbay, E. A., Koyama, S., Carretero, J. I., Altabel, A., Tchaicha, J. H., Christensen, C. L., et al. (2013). Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. *Cancer Discov.* 3, 1355–1363. doi: 10.1158/2159-8290.CD-13-0310

Alsaab, H. O., Sau, S., Alzhrani, R., Tatiparti, K., Bhise, K., Kashaw, S. K., Akbay, E. A., Koyama, S., Carretero, J., Altabef, A., Tchaicha, J. H., Christensen, N. S., Nassif, N. T., and O’Brien, B. A. (2015). Genetic variants of SLC11A1 characterization of gastric adenocarcinoma. *Nature* 513, 202–209. doi: 10.1038/nature13480

Cingolani, P., Platts, A., Wang le, L., Coon, M., Nguyen, T., Wang, L., et al. (2012). A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. *Genes Immun.* 16, 275–283. doi: 10.1038/gene.2015.8

Cunningham, D., Okines, A. F., and Ashley, S. (2010). Capecitabine and *Dev. Immunol.* 236, 219–242.

Dituri, F., Mazzocca, A., Giannelli, G., and Antonaci, S. (2011). PI3K functions in hypersensitivity and arthritis. *J. Clin. Invest.* 121, 721–729. doi: 10.1172/JCI7911

Dituri, F., Mazzocca, A., Giannelli, G., and Antonaci, S. (2011). PI3K functions in cancer progression, anticancer immunity and immune evasion by tumors. *Clin. Dev. Immunol.* 2011:947858. doi: 10.1155/2011/947858

Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., et al. (2015). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int. J. Cancer* 136, E359–E386. doi: 10.1002/ijc.29210

Francisco, L. M., Sage, P. T., and Sharpe, A. H. (2010). The PD-1 pathway in tolerance and autoimmunity. *Immunol. Rev.* 236, 219–242. doi: 10.1111/j.1600-065X.2010.00923.x

Fuchs, C. S., Doi, T., Jang, R. W., Muro, K., Satoh, T., Machado, M., et al. (2018). Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. *JAMA Oncol.* 4:e180013. doi: 10.1001/jamaoncol.2018.0013

Gyoryfi, B., Gyoryfi, A., and Tulassay, Z. (2005). The problem of multiple testing and solutions for genome-wide studies. *Orv. Hetil.* 146, 559–563.

Harada, K., Baba, Y., Shigaki, H., Ishimoto, T., Miyake, K., Kosumi, K., et al. (2016). Prognostic and clinical impact of PIK3CA mutation in gastric cancer: pyrosequencing technology and literature review. *BMC Cancer* 16:400. doi: 10.1186/s12885-016-2422-y

Henick, B. S., Herbst, R. S., and Goldberg, S. B. (2014). The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer. *Expert Opin. Ther. Targets* 18, 1407–1420. doi: 10.1517/14728222.2014.957994

Hothorn, T., Hornik, K., and Zeileis, A. (2006). Unbiased recursive partitioning: a conditional inference framework. *J. Comput. Graph. Stat.* 15, 651–674. doi: 10.1196/106186006X133933

Hothorn, T., and Zeileis, A. (2015). partykit: A Modular Toolkit for Recursive Partitioning in R. Available online at: http://mlr.mlr.jp/papers/v16/hothorn15a.html (Accessed 16).

Huang da, W., Sherman, B. T., and Lempicki, R. A. (2009). Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat. Protoc.* 4, 44–57. doi: 10.1038/nprot.2008.211

Jiang, X., Zhou, J., Giobbie-Hurder, A., Wargo, J., and Hodi, F. S. (2013). The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. *Clin. Cancer Res.* 19, 598–609. doi: 10.1158/1078-0432.CCR-12-2731

Kang, Y. K., Boku, N., Satoh, T., Ryu, M. H., Chao, Y., Kato, K., et al. (2017). Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet* 390, 2461–2471. doi: 10.1016/S0140-6736(17)31827-7

Kim, J. W., Lee, H. S., Nam, K. H., Ahn, S., Kim, J. W., Ahn, S. H., et al. (2017). PIK3CA mutations are associated with increased tumor aggressiveness and Akt activation in gastric cancer. * Oncotarget* 8, 90948–90958. doi: 10.18632/oncotarget.18770

Malvezzi, M., Bonfazi, M., Bertuccio, P., Levi, F., La Vecchia, C., Decarli, A., et al. (2010). An age-period-cohort analysis of gastric cancer mortality from 1950 to 2007 in Europe. *Ann. Epidemiol.* 20, 898–905. doi: 10.1016/j.annepidem.2010.08.013

Menyhárt, O., Fekete, J. T., and Gyoryfi, B. (2018). Demographic shift disproportionately increases cancer burden in an aging nation: current and expected incidence and mortality in Hungary up to 2030. *Clin. Epidemiol.* 10, 1103–1108. doi: 10.2147/CLEP.S155063

Ota, K., Azuma, K., Kawahara, A., Hattori, S., Iwama, E., Tanizaki, J., et al. (2015). Induction of PD-L1 expression by the EML4-ALK oncoprotein and downstream signaling pathways in non-small cell lung cancer. *Clin. Cancer Res.* 21, 4014–4021. doi: 10.1158/1078-0432.CCR-15-0016

Peter, S., Gettinger, S., Johnson, M. L., Janne, P. A., Garassino, M. C., Christoph, D., et al. (2017). Phase II trial of avelumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH). *J. Clin. Oncol.* 35, 2781–2789. doi: 10.1200/JCO.2016.71.9476

Por, J. R., and Marra, M. A. (2016). MEZF transcription factors: developmental regulators and emerging cancer genes. *Oncotarget* 7, 2297–2312. doi: 10.18632/oncotarget.6223

Scanlan, M. J., Gout, I., Gordon, C. M., Williamson, B., Stockert, E., Gure, A. O., et al. (2001). Humoral immunity to human breast cancer: antigen definition and quantitative analysis of mRNA expression. *Cancer Immun.* 1:4.
Schüler, A., Schwieger, M., Engelmann, A., Weber, K., Horn, S., Müller, U., et al. (2008). The MADS transcription factor Mef2c is a pivotal modulator of myeloid cell fate. *Blood* 111, 4532–4541. doi: 10.1182/blood-2007-10-116343

Seeruttun, S. R., Yuan, S., Qiu, H., Huang, Y., Li, Y., Liang, Y., et al. (2017). A comprehensive analysis comparing the eighth AJCC gastric cancer pathological classification to the seventh, sixth, and fifth editions. *Cancer Med.* 6, 2804–2813. doi: 10.1002/cam4.1230

Siemers, N. O., Holloway, J. L., Chang, H., Chasalow, S. D., Ross-MacDonald, P. B., Voliva, C. F., et al. (2017). Genome-wide association analysis identifies genetic correlates of immune infiltrates in solid tumors. *PLoS ONE* 12:e0179726. doi: 10.1371/journal.pone.0179726

Skoulidis, F., Byers, L. A., Diao, L., Papadimitrakopoulou, V. A., Tong, P., Izzo, J., et al. (2015). Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. *Cancer Discov.* 5, 860–877. doi: 10.1158/2159-8290.CD-14-1236

Song, M., Chen, D., Lu, B., Wang, C., Zhang, J., Huang, L., et al. (2013). PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer. *PLoS ONE* 8:e65821. doi: 10.1371/journal.pone.0065821

Taieb, J., Moehler, M., Boku, N., Ajani, J. A., Yañez Ruiz, E., Ryu, M. H., et al. (2018). Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: current status and future perspectives. *Cancer Treat. Rev.* 66, 104–113. doi: 10.1016/j.ctrv.2018.04.004

Teng, F., Meng, X., Kong, L., and Yu, J. (2018). Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: a systematic review. *Cancer Lett.* 414, 166–173. doi: 10.1016/j.canlet.2017.11.014

Varet, H., Brillat-Guiguem, L., Coppée, J. Y., and Dillies, M. A. (2016). SARTools: a DESeq2- and EdgeR-based R pipeline for comprehensive differential analysis of RNA-seq data. *PLoS ONE* 11:e0157022. doi: 10.1371/journal.pone.0157022

Wang, J., Guo, X., Xie, C., and Jiang, J. (2017). KIF15 promotes pancreatic cancer proliferation via the MEK–ERK signalling pathway. *Br. J. Cancer* 117, 245–255. doi: 10.1038/bjc.2017.165

Wu, P., Wu, D., Li, L., Chai, Y., and Huang, J. (2015). PD-L1 and survival in solid tumors: a meta-analysis. *PLoS ONE* 10:e0131403. doi: 10.1371/journal.pone.0131403

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Copyright © 2019 Menyhárt, Pongor and Györffy. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*